Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 4 parts: Part 1 is a single ascending dose (SAD) study in healthy volunteers; Part 2 is a multiple ascending dose (MAD) study in subjects with stable, mild asthma; Part 3 is a repeat dose in patients with moderate to severe asthma and Part 4 is a repeat dose in patients with COPD.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05006521
Study type Interventional
Source Kinaset Therapeutics Inc
Contact
Status Active, not recruiting
Phase Phase 1
Start date July 30, 2021
Completion date April 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT06099145 - Clinical and Medico-economic Validation of the HEPHAI Solution. N/A
Completed NCT06417931 - Medication Adherence and Use of Inhaler Devices in Patients With Asthma or COPD N/A
Completed NCT05764343 - The Effect of Immediate Smoking Cessation Interventions for Smokers With Chronic Airway Diseases N/A
Recruiting NCT06039943 - Relationship Between Acoustic Breath Sounds and Spirometry N/A
Recruiting NCT05299385 - The Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.) Phase 3
Active, not recruiting NCT04341701 - Phenotype Identification Based on Multimodal MRI Analysis of Patients With Bronchial Obstructive Diseases N/A
Recruiting NCT04233190 - A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment Phase 3